34 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Holodniy, Infectious Disease Specialist in Palo Alto, CA?
Dr. Mark Holodniy, MD is an Infectious Disease Specialist, who primarily practices in Palo Alto, CA. He has been practicing for over 34 years and is board certified. Dr. Holodniy completed his residency at Good Samaritan Reg Med Ctr, Internal Medicine. Dr. Holodniy is fluent in English, and is currently seeing new patients. To book an appointment or to confirm insurance options, please call Dr. Holodniy’s office at (650) 852-3408.
What are Areas of Expertise for Dr. Holodniy?
Dr. Mark Holodniy, MD is a highly-rated, board-certified Infectious Disease Specialist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Holodniy empowers patients to confidently navigate their health journey, specializing in HIV/AIDS, and comprehensive wellness support. Serving the Palo Alto, CA community, Dr. Holodniy is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Holodniy go to medical school and complete their residency?
Residency: Good Samaritan Reg Med Ctr, Internal Medicine
Medical School: Northwestern Uniiversity
Is Dr. Holodniy board certified as an Infectious Disease Specialist?
Yes, Dr. Mark Holodniy, MD is board certified by the American Board of Internal Medicine
What languages does Dr. Holodniy speak?
Dr. Holodniy and their clinical team can communicate with patients in the following languages:
English
What conditions does an Infectious Disease Specialist like Dr. Holodniy typically treat?
As an Infectious Disease Specialist, conditions treated by Dr. Mark Holodniy may include:
Please contact Dr. Holodniy's office directly to confirm care for your specific condition, for more information, or to schedule a consultation.
What procedures does an Infectious Disease Specialist like Dr. Holodniy typically perform?
As an Infectious Disease Specialist, procedures performed by Dr. Mark Holodniy may include:
- Epidemiology Consultation
- Epidemiology Follow Up
- HIV / AIDS Consultation
- HIV / AIDS Follow Up
- Human Papillomavirus (HPV) Vaccine
- Infection Follow Up
- Lumbar Puncture
- Pertussis Vaccine
Please contact Dr. Holodniy's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Holodniy accept my insurance?
Please contact Dr. Holodniy's office to confirm accepted insurance plans.
Where is Dr. Holodniy's office located?
Recognitions
Publications
Application of a non-amplification-based technology to detect invasive fungal pathogens
, 2014
Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co
MicroR and hepatitis C virus- challenges in investigation and translation
The VACS Index Accurately Predicts Mortality
, 2014
Human Pegivirus (HPgV or GB virus C) R is found in multiple blood mononuclear cells in vivo and
Public Health Practice Is Not Research.
Cost-Effectiveness of Newer Antiretroviral Drugs in Treatment
, 2013
Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster
, 2013
Concurrent outbreaks with co-infection of norovirus
, 2013
Health-related Quality of Life Assessment after Antiretroviral Therapy: A Review of the Literature.
, 2013
Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review
, 2013
Cost-Effectiveness Alysis of Risk-Factor Guided
, 2013
Dengue Surveillance in Veterans Affairs Healthcare Facilities, 2007-2010
, 2013
Combining Surveillance Systems: Effective Merging of U.S. Veteran and Military Health Data.
, 2013
Immune biomarker differences and changes comparing HCV mono-infected, HIV
, 2013
Influenza treatment and prophylaxis with neuraminidase inhibitors: a review.
, 2013
CD4 Counts and Mortality in Virologically Suppressed US Veterans.
GBV-C viremia and clinical events in advanced HIV infection.
IL28B polymorphism is not associated with HCV protease diversity in patients co
, 2012
Cost Effectiveness of Screening Strategies for Early Identification of HIV
, 2012
Development of Elvitegravir Resistance
, 2012
Predictive value of HIV-1 replication capacity
, 2012
Results from a Large-Scale Epidemiologic Look
, 2012
Comparative Assessment of Antimicrobial Usage Measures in the Department of Veterans Affairs
, 2012
Outcomes Associated with a Cognitive
, 2012
Quantitation of hepatitis C virus R in peripheral blood mononuclear cells in HCV-monoinfection
, 2012
New Protease Inhibitors for the Treatment of Chronic Hepatitis C A Cost-Effectiveness Alysis
, 2012
Ultrasensitive detection of rare mutations using next-generation targeted resequencing
, 2012
Effect of Treatment Interruption
, 2012
HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody
, 2011
Use of dried clinical samples for storing and detecting influenza R
, 2011
Diagnosing invasive fungal disease in critically ill patients
, 2011
IL28B POLYMORPHISM IS NOT ASSOCIATED WITH HCV PROTEASE DIVERSITY IN HIV
, 2011
Enhanced health event detection and influenza surveillance using a joint Veterans Affairs
, 2011
Determints of the Cost of Health Services Used by Veterans With HIV
, 2011
Interferon combition therapy for HIV/hepatitis C virus coinfection
, 2011
One-year outcomes of community-acquired
, 2011
Clinically Significant Drug Interactions in Younger
, 2011
Results of Antiretroviral Treatment Interruption
, 2011
Integrating Tobacco Cessation Into Mental Health Care for Posttraumatic Stress Disorder A R
, 2010
Comparative effectiveness of dried plasma HIV
, 2010
Effect of Home Testing of Intertiol Normalized Ratio on Clinical Events.
, 2010
An evaluation of patient self-testing competency of prothrombin time for maging anticoagulation
, 2010
Materl-Fetal Pharmacokinetics
, 2010
Impact of Interferon-Ribavirin Treatment on Hepatitis C Virus
, 2010
Effect of a Zoster Vaccine on Herpes Zoster-Related Interference with Functiol Status
, 2010
Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials.
, 2010
Is spil tuberculosis contagious?
, 2010
Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial
, 2010
Impact of Highly Active Antiretroviral Therapy on Hepatitis C Virus
, 2010
Effective Detection of the 2009 H1N1 Influenza P
, 2010
Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off
, 2010
Sudden sensorineural hearing loss associated with vardefil.
, 2010
Varicella-Zoster Virus
, 2009
The concurrent validity and responsiveness of the health utilities index
, 2009
Quality of Life of Patients With Advanced HIV
, 2009
Thrombocytopenia from Combition Treatment with Oseltamivir and Probenecid
, 2009
A Real-Time PCR Assay to Identify and Discrimite Among Wild
, 2009
Effect of the MTHFR C677T and A1298C Polymorphisms on Survival
, 2009
Oseltamivir for treatment and prophylaxis of influenza infection
, 2009
Dried-Plasma Transport Using a Novel Matrix
, 2009
Health-Related Quality of Life in a R
, 2009
Infectious complications in OIF/OEF veterans with traumatic brain injury
, 2009
Novel Targets for Antiretroviral Therapy Clinical Progress to Date
, 2009
Health-Related Quality of Life in a R
, 2009
Pharmacokinetics and tolerability of oseltamivir combined with probenecid
, 2008
The Relationship Between HIV Infection and Cardiovascular Disease.
, 2008
Cost-effectiveness of HIV screening in patients older than 55 years of age
, 2008
Frequency of HIV screening in the Veterans Health Administration
, 2008
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine
, 2008
Safety, tolerability
, 2008
Severe pneumonia due to adenovirus serotype 14: A new respiratory threat?
, 2008
HIV infection in the elderly
, 2008
Prevalence of HIV infection among inpatients
, 2007
A systematic review of cost-utility alyses in HIV/AIDS: Implications for public policy
, 2007
Evolution of genotypic resistance algorithms
, 2007
HIV testing of at risk patients in a large integrated health care system
, 2007
Role of Environmental Surveillance in Dtermining the Risk of Hospital-Acquired Legionellosis
, 2007
Representatiol Fluency in HIV Clinical Practice: A Model of Instructor Discourse
, 2007
Daruvir in the treatment of HIV-1 infection - Viewpoint
, 2007
siR delivery into human T cells and primary cells with carbon-notube transporters
, 2007
Relationship between antiretroviral prescribing patterns
, 2007
HIV-1 load quantitation: A 17-year perspective
, 2006
Prevention of shingles by varicella zoster virus vaccition
, 2006
Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus
, 2006
The effect of diagnosis with HIV infection on health-related quality of life
, 2006
Evolution of genotypic resistance algorithms
, 2006
The safety and tolerability of Z-100 in patients infected with HIV-1
, 2006
Utilization and access to Antiretroviral genotypic resistance testing and results within the US
, 2006
Case files from Stanford University Medical Center
, 2006
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation
, 2005
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
, 2005
Proteomic alysis of serum cytokine levels in response to highly active antiretroviral therapy
, 2005
Clinical utility of viral load measurements
, 2005
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy
, 2005
Prevalence of antiretroviral drug resistance in the HIV-1
, 2004
Multicenter evaluation of the performance characteristics of the Bayer VERSANT HCV R 3.0 assay (bD)
, 2004
Inhibition of HIV infectivity by a tural human isolate of Lactobacillus jensenii engineered to
, 2003
High levels of adherence do not prevent accumulation of HIV drug resistance mutations
, 2003
An open-label randomized clinical trial of novel therapeutic strategies for HIV
, 2003
Successful magement of dissemited Nocardia transvalensis infection
, 2003
Accuracy of the TRUGENE HIV-1 genotyping kit
, 2003
Impact of highly active antiretroviral therapy
, 2003
Role of Deoxyribonucleoside Kises
, 2003
HIV-1 R and viral load
, 2002
A pilot trial of indivir, ritovir
, 2001
Multinodular polymyositis in a patient with human immunodeficiency
, 2001
HIV resistance testing--has it come of age?
, 2000
Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture
, 2000
Adherence to protease inhibitors, HIV-1 viral load
, 2000
Stability of plasma human immunodeficiency virus load
, 2000
A double blind, randomized
, 1999
Decreased medical expenditures for care of HIV-seropositive patients
, 1999
Viral Load Monitoring in HIV Infection.
, 1999
Effects of c
What is Dr. Holodniy's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Holodniy's National Provider Identifier (NPI) number is 1073533238.
What common questions do patients ask about Dr. Holodniy?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Holodniy
What is Dr. Mark Holodniy's specialty?
Dr. Holodniy is a Infectious Disease Specialist near Palo Alto, CA.
What does an Infectious Disease Specialist do?
An internist who deals with infectious diseases of all types and in all organ systems. Conditions requiring selective use of antibiotics call for this special skill. This physician often diagnoses and treats AIDS patients and patients with fevers which have not been explained. Infectious disease specialists may also have expertise in preventive medicine and travel medicine.
Is this Dr. Mark Holodniy affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Holodniy is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see an Infectious Disease Specialist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see an Infectious Disease Specialist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Mark Holodniy accepting new patients in Palo Alto, CA?
Yes, Dr. Mark Holodniy is accepting new patients at this time.
Does Dr. Mark Holodniy offer online booking?
Please contact Dr. Holodniy's office at (650) 852-3408 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Mark Holodniy?
Please contact Dr. Holodniy's office at (650) 852-3408 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Mark Holodniy have?
Dr. Mark Holodniy is certified by the American Board of Internal Medicine.
Other Infectious Disease Specialist Near Palo Alto, CA
Infectious Disease Specialist
Accepting patients
Infectious Disease Specialist
Accepting patientsInfectious Disease Specialist
Accepting patients